2.50
Hdl Handle:
http://hdl.handle.net/10541/99443
Title:
5T4 oncofetal antigen expression in ovarian carcinoma.
Authors:
Wrigley, E; McGown, Alan T; Rennison, J; Swindell, Ric; Crowther, Derek; Starzynska, T; Stern, Peter L
Abstract:
5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many different carcinomas but detected only at low levels in some normal epithelia. Analysis of the patterns of expression of 5T4 oncofetal antigen in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumor cells and metastatic spread. The 5T4 antigen expression of 72 epithelial ovarian carcinomas has been investigated by immunohistochemistry; 71% of the carcinomas demonstrated positive 5T4 immunoreactivity in adenocarcinoma cells and/or associated stromal tissue. In order to assess any relationship to prognosis, the 5T4 phenotypes were analyzed with respect to various clinicopathologic features of the tumors and the clinical outcome of the patients assessed by survival and disease-free interval. There was a significant correlation between 5T4 expression and more advanced stage of disease (FIGO stages III and IV) (P < 0.001) and with poorly differentiated tumors (P = 0.036) compared to well or moderately differentiated tumors. Patients with tumors expressing 5T4 were less likely to respond well to adjuvant therapy (P = 0.030) and had a significantly worse outlook in terms of survival (P = 0.033) and disease-free interval (P = 0.033). This significance was not demonstrated as acting independently of FIGO stage and tumor differentiation.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, CRC Department of Experimental Chemotherapy, Paterson Institute, CRC Department of Medical Statistics, Christie Hospital, CRC Department of Immunology, Paterson Institute, Manchester, UK.
Citation:
5T4 oncofetal antigen expression in ovarian carcinoma. 1995, 5 (4):269-274 Int. J. Gynecol. Cancer
Journal:
International Journal of Gynecological Cancer
Issue Date:
Jul-1995
URI:
http://hdl.handle.net/10541/99443
DOI:
10.1046/j.1525-1438.1995.05040269.x
PubMed ID:
11578488
Type:
Article
Language:
en
ISSN:
1525-1438
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorWrigley, Een
dc.contributor.authorMcGown, Alan Ten
dc.contributor.authorRennison, Jen
dc.contributor.authorSwindell, Ricen
dc.contributor.authorCrowther, Dereken
dc.contributor.authorStarzynska, Ten
dc.contributor.authorStern, Peter Len
dc.date.accessioned2010-05-20T15:21:25Z-
dc.date.available2010-05-20T15:21:25Z-
dc.date.issued1995-07-
dc.identifier.citation5T4 oncofetal antigen expression in ovarian carcinoma. 1995, 5 (4):269-274 Int. J. Gynecol. Canceren
dc.identifier.issn1525-1438-
dc.identifier.pmid11578488-
dc.identifier.doi10.1046/j.1525-1438.1995.05040269.x-
dc.identifier.urihttp://hdl.handle.net/10541/99443-
dc.description.abstract5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many different carcinomas but detected only at low levels in some normal epithelia. Analysis of the patterns of expression of 5T4 oncofetal antigen in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumor cells and metastatic spread. The 5T4 antigen expression of 72 epithelial ovarian carcinomas has been investigated by immunohistochemistry; 71% of the carcinomas demonstrated positive 5T4 immunoreactivity in adenocarcinoma cells and/or associated stromal tissue. In order to assess any relationship to prognosis, the 5T4 phenotypes were analyzed with respect to various clinicopathologic features of the tumors and the clinical outcome of the patients assessed by survival and disease-free interval. There was a significant correlation between 5T4 expression and more advanced stage of disease (FIGO stages III and IV) (P < 0.001) and with poorly differentiated tumors (P = 0.036) compared to well or moderately differentiated tumors. Patients with tumors expressing 5T4 were less likely to respond well to adjuvant therapy (P = 0.030) and had a significantly worse outlook in terms of survival (P = 0.033) and disease-free interval (P = 0.033). This significance was not demonstrated as acting independently of FIGO stage and tumor differentiation.en
dc.languageENG-
dc.language.isoenen
dc.subject5T4 Oncofoetal Antigenen
dc.subjectOvarian Carcinomaen
dc.subjectSurvivalen
dc.title5T4 oncofetal antigen expression in ovarian carcinoma.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, CRC Department of Experimental Chemotherapy, Paterson Institute, CRC Department of Medical Statistics, Christie Hospital, CRC Department of Immunology, Paterson Institute, Manchester, UK.en
dc.identifier.journalInternational Journal of Gynecological Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.